Issued heat shock protein (HSP) patents
 Patent downloads
require the free Adobe Reader.Recently, the European Patent Office issued a decision in favor of Stressgen Biotechnologies in response to a patent challenge by Antigenics regarding use of HSP E7. This decision has no impact on Antigenics’ current or prospective development programs.
Click on the patent numbers below to download each PDF file.
| US Patent No. |
Date Issued |
Coverage |
| 7,186,515 |
Mar. 6, 2007 |
Methods for identifying compounds (including antibodies) that modulate the interaction of HSPs with the HSP receptor, CD91. |
| 7,179,462 |
Feb. 20, 2007 |
Methods of treating autoimmune diseases with anti-CD91 antibodies. |
| 7,132,109 |
Nov. 7, 2006 |
Method of treating cancer with generic HSP in combination with a cancer vaccine. |
| 6,984,389 |
Jan. 10, 2006 |
Method of treating cancer with HSP-peptide complexes in combination with tyrosine kinase inhibitors (like Gleevec). |
| 6,797,480 |
Sept. 28, 2004 |
Methods for screening molecules for the
ability to modulate heat shock protein receptor activity. |
| 6,610,659 |
Aug. 26, 2003 |
Compositions of peptides that are eluted
from HSP70 isolated from mammalian tumor cells |
| 6,475,490 |
Nov. 5, 2002 |
Methods of promoting healing of skin wounds
by administering purified heat shock proteins (HSPs) or
HSP-peptide complexes |
| 6,468,540 |
Oct. 22, 2002 |
Composition of HSP-peptide complexes isolated
from tumors of household pets |
| 6,461,615 |
Oct. 8, 2002 |
Treating or preventing infectious diseases
by administering HSP-antigen complexes that are made in
vitro |
| 6,455,503 |
Sept. 24, 2002 |
A composition of peptides that are eluted
from HSPs isolated from pathogen-infected cells and a composition
of such eluted peptides and an adjuvant |
| 6,455,048 |
Sept. 24, 2002 |
Methods of preventing cancer with doses
of HSP70 below 10 micrograms |
| 6,451,316 |
Sept. 17, 2002 |
Methods of using HSP-peptide complexes to
expand antigen-specific T cells in vitro |
| 6,447,781 |
Sept. 10, 2002 |
Methods of preventing cancer using HSPs
complexed to antigens in vitro |
| 6,447,780 |
Sept. 10, 2002 |
Methods of preventing cancer with doses
of HSP90 below 50 micrograms |
| 6,436,404 |
Aug. 20, 2002 |
Methods of preventing cancer with doses
of gp96 below 10 micrograms |
| 6,410,028 |
June 25, 2002 |
Methods of eliciting immune response using
HSPs complexed to proteins or peptides in vitro |
| 6,410,027 |
June 25, 2002 |
Medical applications of HSPs in patients
with small tumors |
| 6,410,026 |
June 25, 2002 |
Medical applications of HSPs in patients
with small tumors |
| 6,406,700 |
June 18, 2002 |
Methods of preventing cancer using HSPs |
| 6,403,095 |
June 11, 2002 |
Methods of treating cancer with doses of
HSP70 below 10 micrograms |
| 6,399,070 |
June 4, 2002 |
Methods of eliciting immune response with
doses of HSP90 below 50 micrograms |
| 6,399,069 |
June 4, 2002 |
Methods of preventing infectious diseases
with doses of HSP70 below 10 micrograms |
| 6,391,306 |
May 21, 2002 |
Methods of treating infectious diseases
with doses of HSP90 below 50 micrograms |
| 6,387,374 |
May 14, 2002 |
Methods of treating cancer with doses of
HSP90 below 50 micrograms |
| 6,383,494 |
May 7, 2002 |
Methods of eliciting immune response with
doses of gp96 below 10 micrograms |
| 6,383,493 |
May 7, 2002 |
Methods of eliciting immune response with
doses of HSP70 below 10 micrograms |
| 6,383,492 |
May 7, 2002 |
Methods of treating infectious diseases
with doses of gp96 below 10 micrograms |
| 6,383,491 |
May 7, 2002 |
Methods of preventing infectious diseases
with doses of HSP90 below 50 micrograms |
| 6,379,672 |
Apr. 30, 2002 |
Methods of preventing infectious diseases
with doses of gp96 below 10 micrograms |
| 6,375,953 |
Apr. 23, 2002 |
Methods of treating infectious diseases
with doses of HSP70 below 10 micrograms |
| 6,322,790 |
Nov. 27, 2001 |
Method of eliciting immune response by administering
HSP-antigen complexes in combination with dendritic cells
that were previously sensitized with HSP-antigen complexes
in vitro. |
| 6,187,312 |
Feb. 13, 2001 |
Methods of treating or preventing infectious
diseases with low doses of HSP90 |
| 6,168,793 |
Jan. 2, 2001 |
Methods of eliciting immune response and
treating cancer or infectious diseases with HSP70 |
| 6,162,436 |
Dec. 19, 2000 |
Methods of treating cancer with low doses
of HSP90. |
| 6,156,302 |
Dec. 5, 2000 |
Methods of preventing and treating infectious
diseases with antigen presenting cells sensitized in vitro
with HSP-antigen complexes. |
| 6,143,299 |
Nov. 7, 2000 |
Methods of treating or preventing infectious
diseases with low doses of gp96. |
| 6,139,841 |
Oct. 31, 2000 |
Methods of treating or preventing infectious
diseases with low doses of HSP70. |
| 6,136,315 |
Oct. 24, 2000 |
Methods of treating cancer with low doses
of HSP70. |
| 6,048,530 |
Apr. 11, 2000 |
Methods of preparing compositions of HSPs
complexed to pathogen-derived peptides. |
| 6,030,618 |
Feb. 29, 2000 |
Compositions of HSPs and antigenic peptides
(from cancers or pathogens) that are complexed in vitro as
well as methods of eliciting immune response with the compositions |
| 6,017,544 |
Jan. 25, 2000 |
Methods of treating cancer and eliciting
an immune response with mammalian HSP-peptide complexes
in combination with cytokines. Also covers compositions
comprising HSPs and cytokines. |
| 6,017,540 |
Jan. 25, 2000 |
Methods of treating cancer with doses of
gp96 below 10 micrograms |
| 6,007,821 |
Dec. 28, 1999 |
Method of treatment of autoimmune diseases
such as diabetes and multiple sclerosis with mammalian
HSPs. |
| 5,997,873 |
Dec. 7 1999 |
Methods of preparing noncovalent complexes
of HSPs and peptides from tumor tissue or from pathogen-infected
cells |
| 5,985,270 |
Nov. 16, 1999 |
Methods of preventing and treating cancer
with antigen-presenting cells sensitized in vitro with
HSP-antigen complexes that are purified from individual
patients' tumors |
| 5,961,979 |
Oct. 5, 1999 |
Nonautologous complexes of HSPs and antigenic
peptides produced in vitro as well as methods of
treating infectious diseases with HSP-peptide complexes
purified from pathogen-infected cells. |
| 5,948,646 |
Sept. 7, 1999 |
Methods of producing unlimited quantities
of HSP-peptide complexes from small tumor samples |
| 5,935,576 |
Aug. 10, 1999 |
Methods of treating cancer with any HSP
that is complexed in vitro with a tumor antigen |
| 5,837,251 |
Nov. 17, 1998 |
Methods of preventing and treating all types
of cancer and methods of eliciting tumor-specific immune
response using lower than expected doses of HSPs |
| 5,830,464 |
Nov. 3, 1998 |
Methods of preventing and treating cancer
with antigen-presenting cells sensitized in vitro with
HSP-antigen complexes that are purified from individual
patients' tumors. |
| 5,750,119 |
May 12, 1998 |
Methods of treating all types of cancer
and methods of eliciting tumor-specific immune response
using all mammalian HSPs (including HSP70-, HSP90- and
gp96-antigen complexes) as well as compositions of tumor-derived
HSP-antigen complexes. |
 Press
releases related to Antigenics patents
Press
releases related to HSP technology
|
